Goldman Sachs
CGON icon

Goldman Sachs’s CG Oncology CGON Stock Holding History

Goldman Sachs’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.9M Sell
857,713
-301,526
-26% -$19.7M 0.01% 1642
2026
Q1 		$78.5M Sell
1,159,239
-165,364
-12% -$9.37M 0.01% 1216
2025
Q4 		$55M Sell
1,324,603
-42,268
-3% -$1.75M 0.01% 1438
2025
Q3 		$55.1M Buy
1,366,871
+179,770
+15% +$5.23M 0.01% 1346
2025
Q2 		$30.9M Buy
1,187,101
+419,835
+55% +$10.1M ﹤0.01% 1727
2025
Q1 		$18.8M Sell
767,266
-51,401
-6% -$1.45M ﹤0.01% 2093
2024
Q4 		$23.5M Buy
818,667
+169,093
+26% +$5.79M ﹤0.01% 1968
2024
Q3 		$24.5M Buy
649,574
+178,484
+38% +$6.26M ﹤0.01% 1880
2024
Q2 		$14.9M Buy
+471,090
New +$16.3M ﹤0.01% 2125

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs's CGON Position: Q2 2026 in Review

Goldman Sachs reduced its CG Oncology (CGON) stake by 26% in Q2 2026, selling an estimated $19.7M and leaving 857,713 shares worth $60.9M. The position accounts for 0.01% of the portfolio, ranked #1642.

Goldman Sachs first reported a position in CGON in Q2 2024 and has held it in 9 quarters since. The position peaked at $78.5M in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Goldman Sachs held 857,713 shares of CG Oncology worth $60.9M as of Q2 2026.
  • Goldman Sachs sold 301,526 CG Oncology shares in Q2 2026, an estimated $19.7M.
  • CG Oncology made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1642 holding.
  • Goldman Sachs first reported a position in CG Oncology in Q2 2024 and has held it in 9 quarters since.
  • Goldman Sachs's CG Oncology position peaked at $78.5M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.